Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens

Blood

Volumn 95, Issue 5, 2000, Pages 1735-1742

  Bang, K W Annie ^a   Speck, Edwin R ^a   Blanchette, Victor S ^a   Freedman, John ^a   Semple, John W ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREFELDIN A; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN; NITRIC OXIDE;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; FEMALE; FLOW CYTOMETRY; IMMUNIZATION; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0034161583     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.5.1735.005k47_1735_1742     Document Type: Article

References (49)

1. DeFranco AL B-lymphocyte activation. In: Paul WE, ed. Fundamental Immunology. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:225.
2. Benoist C, Mathis D. T-lymphocyte differentiation and biology. In: Paul WE, ed. Fundamental Immunology. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:367.
3. Ziegler HK, Unanue ER. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci U SA. 1982;79:175.
4. Shimonkevitz R, Kappler J, Marrack P, Grey H. Antigen recognition by H-2 restricted T cells. I. Cell free antigen processing. J Exp Med. 1983;158:303.
5. Allen PM, Unanue ER. Differential requirements for antigen processing by macrophages for lysozyme-specitic T cell hybridomas. J Immunol. 1984;132:1077.
6. Lee P, Matsueda GR, Allen PM. T cell recognition of fibrinogen: a determinant on the Aα-chain does not require processing. J Immunol. 1988;140:1063
7. Régnier-Vigoureux A, el Ayeb M, Defendini ML, Granier C, Pierres M. Processing by accessory cells for presentation to murine T cells of apamin, a disulfide-bonded 18 amino acid peptide. J Immunol. 1988;140:1069.
8. Stern LJ, Wiley DC. Antigenic peptide binding by class I and class II histocompatibility proteins. Structure. 1994;2:245.
9. Betsofsky JA, Berkower IJ. Immunogenicity and antigen structure. In: Paul WE, ed. Fundamental Immunology. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:651.
10. Paul WE. Antigen processing and presentation. In: Gallen JL, Goldstein I, Snyderman R, eds. Inflammation, Basic Principles and Clinical Correlates. New York, NY: Raven Press; 1992:776.
11. Henkert PA. Cytotoxic T lymphocytes. In: Paul WE, ed. Fundamental Immunology. Philadelphia, PA: Lippincott Williams & Wilkins; 1999;1021.
12. Morrison LA, Llukacher AE, Braciale VL, Fan D, Braciale TJ. Differences in antigen presentation to MHC class I and class II-restricted influenza virus specific cytolytic T lymphocyte clones. J Exp Med. 1986;163:903.
13. Nuchtern JG, Biddison WE, Klausner RD. Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature. 1990;343:74.
14. Jacobson S, Sekaly RP, Jacobson CL, McFarland HF, Long EO. HLA class II-restricted presentation of cytoplasmic measles virus antigen to cytotoxic T cells. J Virol. 1989;63:1756.
15. Shoskes DA, Wood KJ. Indirect presentation of MHC antigens in transplantation. Immunol Today. 1994;2:103.
16. Gould DS, Auchincloss H Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today. 1999;20:77.
17. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N. Monitoring of soluble HLA antigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Transplantation. 1996;61:566.
18. Benham AM, Sawyer GJ, Fabre JW. Indirect T cell allorecognition of donor antigens contributes to the rejection of vascularized kidney allografts. Transplantation. 1995;59:1028.
19. Fangman J, Dalchau R, Fabre JW. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med. 1992;175:1521.
20. Lee RS, Grusby MJ, Glimcher LH, Winn HJ, Auchincloss H Jr. Indirect recognition by helper cells can induce donor-specific cytotoxic T lymphocytes in vivo. J Exp Med. 1994;179:865.
21. Sayegh MH, Watschinger B, Carpenter CB, Mechanisms of T cell recognition of alloantigen: the role of peptides. Transplantation. 1994;57:1295.
22. Auchincloss H Jr, Sultan H. Antigen processing and presentation in transplantation. Curr Opin Immunol. 1996;8:681.
23. Semple JW, Speck ER, Milev YP, Blanchette V, Freedman J. Indirect allorecognition of platelets by T helper cells during platelet transfusions correlate with anti-MHC antibody and cytotoxic T lymphocyte formation. Blood. 1995;86:805.
24. Oh JH, Taysavang, Whelchel JD. Conferring immunogenteity to platelets by preincubation with recipients' adherent cells [abstract]. Proceedings of the IX International Congress of Immunology. San Francisco, CA, July 23-29, 1995:69.
25. Bang A, Speck ER, Blanchette VS, Freedman J, Semple JW. Recipient humoral immunity against leukoreduced allogeneic platelets is suppressed by aminoguanidine, selective inhibitor of inducible nitric oxide synthase. Blood. 1996;88:2959.
26. Semple JW, Speck ER, Cosgrave D, Lazarus AH, Blanchette VS, Freedman J. Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity. Blood. 1999;93:713.
27. Nordhagen R, Flaathen ST. Chloroquine removal of HLA antigens from platelets for the platelet immunofluorescence test. Vox Sang 1985;48:156.
28. Freedman J, Hornstein A. Simple method for differentiating between HLA and platelet-specific antibodies by flow cytometry. Am J Hematol. 1991;38:314.
29. Griffiths MJD, Messent M, MacAllister RJ, Evans TW. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol. 1993;110:963.
30. Wolff DJ, Lubeskie A. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch Biochem Biophys. 1995;316:290.
31. Perez-Ramirez B, Gorbunoff MJ, Timashefl SN. Linkages in tubulin-colchicine function: the role of the ring C (C′) oxygens and ring B in the controls. Biochemistry. 1998;37:1646.
32. Fang FC. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest. 1997;99:2818.
33. Rotrosen D. The respiratory burst oxidase. In: Gallen JL, Goldstein I, Snyderman R, eds. Inflammation, Basic Principles and Clinical Correlates. New York, NY: Raven Press; 1992:589.
34. Kaufmann SHE. Immunity to intracellular bacteria. In: Paul WE, ed. Fundamental Immunology. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:1335.
35. Clancy RJ, Leszczynska J, Amin A, Levartovsky D, Abramson SB. Nitric oxide stimulates ADP ribosylation of actin in association with the inhibition of actin polymerization in human neutrophils. J Leukoc Biol. 1995;58:196.
36. Liu SM, Sundqvist T. Involvement of nitric oxide in permeability alteration and F-actin redistribution induced by phorbol myristate acetate in endothelial cells. Exp Cell Res. 1995;221:289.
37. Germain RN. Immunogenicity and antigen structure. In: Paul WE, ed. Fundamental Immunology. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:669.
38. Reid PA, Watts C. Cycling of cell-surface MHC glycoproteins through primaquine-sensitive intracellular compartments. Nature. 1990;346:655B657.
39. Weber DA, Buck LB, Delohery TM, Agostino N, Pernis B. Class II MHC molecules are spontaneously internalized in acidic endosomes by activated B cells. J Mol Cell Immunol. 1990;4:255-266.
40. Semple JW, Speck ER, Blanchette V, Freedman J. Immune non-responsiveness to allogeneic platelets in murine strains which lack MHC class II I-E molecules is due to the presence of CD8+ T cells [abstract]. Blood. 1996:88(suppl 1):162a.
41. Revel M, Chebath J. Interferon-activated genes. Trends Biochem Sci. 1986;11:166.
42. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749.
43. Griffiths MJD, Massent M, MacAllister RJ, Evans TW. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol. 1993;110:963.
44. Wolff DJ, Lubeskie A. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch Biochem Biophys. 1995;316:290.
45. Donnenberg MS, Donohue-Rolfe A, Keusch GT. A comparison of Hep-2 cell invasion by enteropathogenic and enteroinvasive E. coli FEMS Microbiol Lett. 1990;57:83.
46. Harding CV, Unanue ER. Cellular mechanism of antigen processing and the function of class I and El major histocompatibility complex molecules. Cell Regulation. 1990;1:499.
47. Thorens B, Vassalli P. Chloroquine and ammonium chloride prevent terminal glycosylation of immunoglobulins in plasma cells without affecting secretion. Nature 1986;321:618.
48. Yewdell JW, Bennink JR. Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. Science. 1989;244:1072.
49. Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994;78:761.